Michael J Overman

Summary

Affiliation: The University of Texas
Country: USA

Publications

  1. pmc Gene expression profiling of ampullary carcinomas classifies ampullary carcinomas into biliary-like and intestinal-like subtypes that are prognostic of outcome
    Michael J Overman
    Department of Gastrointestinal Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas, United States of America
    PLoS ONE 8:e65144. 2013
  2. pmc Improving the AJCC/TNM staging for adenocarcinomas of the appendix: the prognostic impact of histological grade
    Michael J Overman
    Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Ann Surg 257:1072-8. 2013
  3. ncbi request reprint Use of research biopsies in clinical trials: are risks and benefits adequately discussed?
    Michael J Overman
    Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    J Clin Oncol 31:17-22. 2013
  4. pmc A population-based comparison of adenocarcinoma of the large and small intestine: insights into a rare disease
    Michael J Overman
    Department of Gastrointestinal Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA
    Ann Surg Oncol 19:1439-45. 2012
  5. ncbi request reprint Worsening of thrombotic thromboctyopenic purpura symptoms associated with desmopressin administration
    Michael Overman
    MD Anderson Cancer Centre, Unit 10, 1515 Holcombe Blvd, Houston, Texas 77030, USA
    Thromb Haemost 92:886-7. 2004
  6. doi request reprint Weekly docetaxel, cisplatin, and 5-fluorouracil as initial therapy for patients with advanced gastric and esophageal cancer
    Michael J Overman
    Department of Gastrointestinal Medical Oncology, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 426, Houston, TX 77030, USA
    Cancer 116:1446-53. 2010
  7. doi request reprint Is there a role for adjuvant therapy in resected adenocarcinoma of the small intestine
    Michael J Overman
    Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Acta Oncol 49:474-9. 2010
  8. ncbi request reprint Oxaliplatin-mediated increase in spleen size as a biomarker for the development of hepatic sinusoidal injury
    Michael J Overman
    Department of Gastrointestinal Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    J Clin Oncol 28:2549-55. 2010
  9. ncbi request reprint Prognostic value of lymph node evaluation in small bowel adenocarcinoma: analysis of the surveillance, epidemiology, and end results database
    Michael J Overman
    Department of Gastrointestinal Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 116:5374-82. 2010
  10. pmc Immunophenotype and molecular characterisation of adenocarcinoma of the small intestine
    M J Overman
    Department of Gastrointestinal Medical Oncology, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Br J Cancer 102:144-50. 2010

Detail Information

Publications35

  1. pmc Gene expression profiling of ampullary carcinomas classifies ampullary carcinomas into biliary-like and intestinal-like subtypes that are prognostic of outcome
    Michael J Overman
    Department of Gastrointestinal Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas, United States of America
    PLoS ONE 8:e65144. 2013
    ..We sought to molecularly classify ampullary adenocarcinomas in comparison to known adenocarcinomas of the pancreas, bile duct, and duodenum by gene expression analysis...
  2. pmc Improving the AJCC/TNM staging for adenocarcinomas of the appendix: the prognostic impact of histological grade
    Michael J Overman
    Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Ann Surg 257:1072-8. 2013
    ....
  3. ncbi request reprint Use of research biopsies in clinical trials: are risks and benefits adequately discussed?
    Michael J Overman
    Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    J Clin Oncol 31:17-22. 2013
    ..Although the incorporation of research biopsies into clinical trials is increasing, limited information is available about how study protocols and informed consents integrate and describe their use...
  4. pmc A population-based comparison of adenocarcinoma of the large and small intestine: insights into a rare disease
    Michael J Overman
    Department of Gastrointestinal Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA
    Ann Surg Oncol 19:1439-45. 2012
    ..Because of its rarity, adenocarcinoma of the small intestine is frequently compared to adenocarcinoma of the colon, although the validity of this comparison is not known...
  5. ncbi request reprint Worsening of thrombotic thromboctyopenic purpura symptoms associated with desmopressin administration
    Michael Overman
    MD Anderson Cancer Centre, Unit 10, 1515 Holcombe Blvd, Houston, Texas 77030, USA
    Thromb Haemost 92:886-7. 2004
  6. doi request reprint Weekly docetaxel, cisplatin, and 5-fluorouracil as initial therapy for patients with advanced gastric and esophageal cancer
    Michael J Overman
    Department of Gastrointestinal Medical Oncology, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 426, Houston, TX 77030, USA
    Cancer 116:1446-53. 2010
    ..The objective of the current study was to evaluate the efficacy and tolerability of a weekly formulation of DCF...
  7. doi request reprint Is there a role for adjuvant therapy in resected adenocarcinoma of the small intestine
    Michael J Overman
    Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Acta Oncol 49:474-9. 2010
    ..We undertook a retrospective analysis to evaluate the benefit of adjuvant therapy in a clearly defined patient population with curatively resected small bowel adenocarcinoma...
  8. ncbi request reprint Oxaliplatin-mediated increase in spleen size as a biomarker for the development of hepatic sinusoidal injury
    Michael J Overman
    Department of Gastrointestinal Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    J Clin Oncol 28:2549-55. 2010
    ..We sought to explore the relationship between oxaliplatin induced hepatic sinusoidal injury, increases in spleen size, and the subsequent development of thrombocytopenia...
  9. ncbi request reprint Prognostic value of lymph node evaluation in small bowel adenocarcinoma: analysis of the surveillance, epidemiology, and end results database
    Michael J Overman
    Department of Gastrointestinal Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 116:5374-82. 2010
    ..The objective of the current study was to evaluate the impact of the number of positive and negative lymph nodes on survival after curative resection...
  10. pmc Immunophenotype and molecular characterisation of adenocarcinoma of the small intestine
    M J Overman
    Department of Gastrointestinal Medical Oncology, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Br J Cancer 102:144-50. 2010
    ..To better understand the molecular abnormalities in small bowel adenocarcinoma (SBA), we characterised a number of candidate oncogenic pathways and the immunophenotype of this rare cancer...
  11. ncbi request reprint Phase 1 study of TAS-102 administered once daily on a 5-day-per-week schedule in patients with solid tumors
    Michael J Overman
    Department of Gastrointestinal Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston Texas, 1515 Holcombe Blvd, Houston, TX, 77030, USA
    Invest New Drugs 26:445-54. 2008
    ..0194 to 0.197 1/h/kg. The recommended phase II doses for TAS-102 are 100 mg/m(2)/day on schedule A and 160 mg/m(2)/day on schedule B. Future development of TAS-102 should focus upon multiple daily dosing schedules...
  12. doi request reprint Chemotherapy with 5-fluorouracil and a platinum compound improves outcomes in metastatic small bowel adenocarcinoma
    Michael J Overman
    Department of Gastrointestinal Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 113:2038-45. 2008
    ..The objective of this retrospective study was to determine whether the addition of a platinum compound to 5-FU provided any benefit in the treatment of patients with metastatic SBA...
  13. doi request reprint Aggressive combined modality therapy for recurrent colorectal cancer involving the duodenum and pancreas: a report of 5 cases
    Michael J Overman
    Department of Gastrointestinal Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77005, USA
    Clin Colorectal Cancer 7:338-42. 2008
    ..Such trimodality therapy can result in durable palliation of symptoms and long-term survival for patients with recurrent CRC involving the duodenum and pancreas, even when other metastases are present...
  14. doi request reprint Phase I clinical study of three times a day oral administration of TAS-102 in patients with solid tumors
    Michael J Overman
    University of Texas, M D Anderson Cancer Center, Houston, Texas, USA
    Cancer Invest 26:794-9. 2008
    ..No responses were noted, but nine patients demonstrated prolonged stable disease in this heavily pretreated 5-FU refractory population...
  15. doi request reprint Phase II study of capecitabine and oxaliplatin for advanced adenocarcinoma of the small bowel and ampulla of Vater
    Michael J Overman
    Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Unit 426, Houston, TX 77030, USA
    J Clin Oncol 27:2598-603. 2009
    ..We conducted a phase II trial to evaluate the benefit of capecitabine in combination with oxaliplatin (CAPOX) in patients with advanced adenocarcinoma of small bowel or ampullary origin...
  16. ncbi request reprint EGFR-targeted therapies in colorectal cancer
    Michael J Overman
    Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
    Dis Colon Rectum 50:1259-70. 2007
    ..The current status of epidermal growth factor receptor-targeted therapeutic agents is reviewed, with emphasis on their role in the management of colorectal cancer...
  17. pmc Adjuvant chemotherapy with FOLFOX for primary colorectal cancer is associated with increased somatic gene mutations and inferior survival in patients undergoing hepatectomy for metachronous liver metastases
    Andreas Andreou
    Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Ann Surg 256:642-50. 2012
    ..We hypothesized that metachronous colorectal liver metastases (CLM) have different biology after failure of oxaliplatin (FOLFOX) compared to 5-fluorouracil (5-FU) or no chemotherapy for adjuvant treatment of colorectal cancer (CRC)...
  18. pmc Is resection of colorectal liver metastases after a second-line chemotherapy regimen justified?
    Antoine Brouquet
    Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
    Cancer 117:4484-92. 2011
    ..Patient outcomes following resection of colorectal liver metastases (CLM) after second-line chemotherapy regimen is unknown...
  19. doi request reprint Pathologic response to preoperative chemotherapy: a new outcome end point after resection of hepatic colorectal metastases
    Dan G Blazer
    Department of Surgical Oncology, Gastrointestinal Medical Oncology, and Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030 4009, USA
    J Clin Oncol 26:5344-51. 2008
    ..The secondary goal of the study was to identify the clinical predictors of pathologic response...
  20. pmc Improved survival in metastatic colorectal cancer is associated with adoption of hepatic resection and improved chemotherapy
    Scott Kopetz
    Department of Gastrointestinal Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX, USA
    J Clin Oncol 27:3677-83. 2009
    ....
  21. ncbi request reprint Surgical strategies for synchronous colorectal liver metastases in 156 consecutive patients: classic, combined or reverse strategy?
    Antoine Brouquet
    Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    J Am Coll Surg 210:934-41. 2010
    ..An increasing number of patients with synchronous colorectal liver metastases (CLM) are candidates for resection. The optimal treatment sequence in these patients has not been defined...
  22. pmc High survival rate after two-stage resection of advanced colorectal liver metastases: response-based selection and complete resection define outcome
    Antoine Brouquet
    Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Unit 444, Houston, TX 77030, USA
    J Clin Oncol 29:1083-90. 2011
    ..The impact of complete resection in this well-selected group is controversial...
  23. pmc Phase II trial of infusional fluorouracil, irinotecan, and bevacizumab for metastatic colorectal cancer: efficacy and circulating angiogenic biomarkers associated with therapeutic resistance
    Scott Kopetz
    University of Texas MD Anderson Cancer Center Lyndon B Johnson Hospital, Harris County Hospital District, Houston, TX, USA
    J Clin Oncol 28:453-9. 2010
    ....
  24. ncbi request reprint Clinicopathologic features and prognosis of duodenal adenocarcinoma and comparison with ampullary and pancreatic ductal adenocarcinoma
    Maryam Zenali
    Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030
    Hum Pathol 44:2792-8. 2013
    ..Patients with DAC had less frequent nodal metastasis and better prognosis than those with PDA. There was no significant difference in prognosis between DAC and AA. ..
  25. doi request reprint Fatal diffuse alveolar damage associated with oxaliplatin administration
    Jack Watkins
    Division of Pharmacy, The University of Texas MD Anderson Cancer Center, Houston, USA
    Clin Colorectal Cancer 10:198-202. 2011
    ..Other cases of pulmonary toxicity associated with oxaliplatin use are presented and the proposed pathophysiology of this rare occurrence is discussed...
  26. ncbi request reprint Modern systemic chemotherapy in surgically unresectable neoplasms of appendiceal origin: a single-institution experience
    Jamie F Shapiro
    Division of Pharmacy, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030 1402, USA
    Cancer 116:316-22. 2010
    ..A retrospective analysis was conducted to determine the benefit of modern systemic chemotherapy in patients with disseminated appendiceal neoplasm who were not considered optimal candidates for cytoreductive surgery...
  27. ncbi request reprint Portal hypertension associated with oxaliplatin administration: clinical manifestations of hepatic sinusoidal injury
    Julian H Slade
    Department of Pharmacy, The University of Texas M D Anderson Cancer Center, Houston, 77030, USA
    Clin Colorectal Cancer 8:225-30. 2009
    ..The literature on hepatic sinusoidal injury after oxaliplatin is reviewed and the proposed pathophysiology is discussed...
  28. ncbi request reprint Target-based therapeutic matching in early-phase clinical trials in patients with advanced colorectal cancer and PIK3CA mutations
    Prasanth Ganesan
    Corresponding Author Filip Janku, Department of Investigational Cancer Therapeutics Phase I Clinical Trials Program, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, FC8 2018, Box 0455, Houston, Texas 77030
    Mol Cancer Ther 12:2857-63. 2013
    ..PIK3CA mutations are associated with simultaneous KRAS mutations, possibly accounting for therapeutic resistance...
  29. doi request reprint Palliative venting gastrostomy in patients with malignant bowel obstruction and ascites
    Colette Shaw
    Section of Interventional Radiology, Department of Diagnostic Radiology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
    Ann Surg Oncol 20:497-505. 2013
    ..We report our clinical experience in cases of MBO and ascites that were known to be technically difficult and at increased risk for complications after PDGT placement...
  30. doi request reprint Systematic survey of therapeutic trials for metastatic colorectal cancer: room for improvement in the critical pathway
    Scott Kopetz
    Department of Gastrointestinal Medical Oncology, M D Anderson Cancer Center, 1515 Holcombe Blvd, Box 426, Houston, TX 77030, USA
    J Clin Oncol 26:2000-5. 2008
    ..It is unclear to what extent aspects of this "Critical Path Initiative" have been adopted in trial designs in metastatic colorectal cancer...
  31. ncbi request reprint Oral alpha-lipoic acid to prevent chemotherapy-induced peripheral neuropathy: a randomized, double-blind, placebo-controlled trial
    Ying Guo
    The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Unit 1414, Houston, TX, 77030, USA
    Support Care Cancer 22:1223-31. 2014
    ..We tested whether alpha-lipoic acid (ALA) could decrease the severity of peripheral neuropathy symptoms in patients undergoing platinum-based chemotherapy...
  32. ncbi request reprint High-level microsatellite instability in appendiceal carcinomas
    Melissa W Taggart
    Department of Pathology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Am J Surg Pathol 37:1192-200. 2013
    ....
  33. ncbi request reprint Survival benefit associated with surgical oophorectomy in patients with colorectal cancer metastatic to the ovary
    Christopher R Garrett
    Department of Gastrointestinal Medical Oncology, MD Anderson Cancer Center, Houston, TX 77030 4009, USA
    Clin Colorectal Cancer 11:191-4. 2012
    ..The purpose of this study was to determine the outcome of patients with colorectal cancer metastatic to the ovary and the impact of surgical oophorectomy on the outcome...
  34. doi request reprint Small bowel adenocarcinomas--existing evidence and evolving paradigms
    Kanwal Raghav
    Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Centre, Unit 426, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Nat Rev Clin Oncol 10:534-44. 2013
    ....
  35. doi request reprint Second-line chemotherapy use in metastatic colon cancer varies by disease responsiveness
    Seth Politano
    University of Texas Health Science Center, Houston, TX, USA
    Clin Colorectal Cancer 7:55-9. 2008
    ..However, it is unclear which patient, disease, and treatment characteristics are associated with the utilization of a second-line regimen...